Retrieval of Patient Information After Discontinuation

Terminated

• Conditions: Alzheimer's Disease
• Interventions: Drug: Bapineuzumab

• Registration Number: NCT01658722
• Lead Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Brief Summary

A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12
• Study First Submitted: 2012-03-12
• Status Verified: 2012-08
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Study First Submitted QC: 2012-08-02
• Study First Posted: 2012-08-07
• Last Update Submitted: 2015-08-31
• Last Update Posted: 2015-09-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 169

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Observational	Bapineuzumab	Long term follow-up

Primary Outcome Measures

Name	Time	Method
Dependence Scale	4 years	Caregiver's assessment of a patient's need for assistance